137 related articles for article (PubMed ID: 35779750)
1. S100A10 Is a New Prognostic Biomarker Related to the Malignant Molecular Features and Immunosuppression Process of Adult Gliomas.
Ma K; Chen S; Chen X; Yang C; Yang J
World Neurosurg; 2022 Sep; 165():e650-e663. PubMed ID: 35779750
[TBL] [Abstract][Full Text] [Related]
2. CTSB is a negative prognostic biomarker and therapeutic target associated with immune cells infiltration and immunosuppression in gliomas.
Ma K; Chen X; Liu W; Chen S; Yang C; Yang J
Sci Rep; 2022 Mar; 12(1):4295. PubMed ID: 35277559
[TBL] [Abstract][Full Text] [Related]
3. CD93 is Associated with Glioma-related Malignant Processes and Immunosuppressive Cell Infiltration as an Inspiring Biomarker of Survivance.
Ma K; Chen S; Chen X; Zhao X; Yang J
J Mol Neurosci; 2022 Oct; 72(10):2106-2124. PubMed ID: 36006582
[TBL] [Abstract][Full Text] [Related]
4. PLVAP is associated with glioma-associated malignant processes and immunosuppressive cell infiltration as a promising marker for prognosis.
Ma K; Chen X; Zhao X; Chen S; Yang J
Heliyon; 2022 Aug; 8(8):e10298. PubMed ID: 36033326
[TBL] [Abstract][Full Text] [Related]
5. Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.
Wang PF; Cai HQ; Zhang CB; Li YM; Liu X; Wan JH; Jiang T; Li SW; Yan CX
J Neuroinflammation; 2018 May; 15(1):145. PubMed ID: 29764444
[TBL] [Abstract][Full Text] [Related]
6. ANXA2 is correlated with the molecular features and clinical prognosis of glioma, and acts as a potential marker of immunosuppression.
Ma K; Chen X; Liu W; Yang Y; Chen S; Sun J; Ma C; Wang T; Yang J
Sci Rep; 2021 Oct; 11(1):20839. PubMed ID: 34675316
[TBL] [Abstract][Full Text] [Related]
7. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Li MY; Wang YY; Cai JQ; Zhang CB; Wang KY; Cheng W; Liu YW; Zhang W; Jiang T
PLoS One; 2015; 10(6):e0130872. PubMed ID: 26115094
[TBL] [Abstract][Full Text] [Related]
8. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
9. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
10. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ
Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas.
Kong LW; Chen J; Zhao H; Yao K; Fang SY; Wang Z; Wang YY; Li SW
Sci Rep; 2019 Nov; 9(1):17080. PubMed ID: 31745161
[TBL] [Abstract][Full Text] [Related]
12. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
[TBL] [Abstract][Full Text] [Related]
14. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T
Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617
[TBL] [Abstract][Full Text] [Related]
15. Identification of integrative molecular and clinical profiles of Fibrinogen-like protein 2 in gliomas using 1323 samples.
Song Z; Wang Y; Du Y; Zhang Z; Yuan Y
Int Immunopharmacol; 2020 Nov; 88():106894. PubMed ID: 32858440
[TBL] [Abstract][Full Text] [Related]
16. Radiomics risk score may be a potential imaging biomarker for predicting survival in isocitrate dehydrogenase wild-type lower-grade gliomas.
Park CJ; Han K; Kim H; Ahn SS; Choi YS; Park YW; Chang JH; Kim SH; Jain R; Lee SK
Eur Radiol; 2020 Dec; 30(12):6464-6474. PubMed ID: 32740813
[TBL] [Abstract][Full Text] [Related]
17. DDOST Correlated with Malignancies and Immune Microenvironment in Gliomas.
Chang X; Pan J; Zhao R; Yan T; Wang X; Guo C; Yang Y; Wang G
Front Immunol; 2022; 13():917014. PubMed ID: 35812432
[TBL] [Abstract][Full Text] [Related]
18. Transcriptome profile and clinical characterization of ICOS expression in gliomas.
Wang J; Shi F; Shan A
Front Oncol; 2022; 12():946967. PubMed ID: 36276141
[TBL] [Abstract][Full Text] [Related]
19. Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples.
Di W; Fan W; Wu F; Shi Z; Wang Z; Yu M; Zhai Y; Chang Y; Pan C; Li G; Kahlert UD; Zhang W
Cancer Sci; 2022 Feb; 113(2):756-769. PubMed ID: 34881489
[TBL] [Abstract][Full Text] [Related]
20. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas.
Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X
Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
